611 related articles for article (PubMed ID: 18192802)
1. Bone marrow-derived mesenchymal stem cells for treatment of heart failure: is it all paracrine actions and immunomodulation?
Mishra PK
J Cardiovasc Med (Hagerstown); 2008 Feb; 9(2):122-8. PubMed ID: 18192802
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells.
Puissant B; Barreau C; Bourin P; Clavel C; Corre J; Bousquet C; Taureau C; Cousin B; Abbal M; Laharrague P; Penicaud L; Casteilla L; Blancher A
Br J Haematol; 2005 Apr; 129(1):118-29. PubMed ID: 15801964
[TBL] [Abstract][Full Text] [Related]
3. Advances in cell-based therapy for structural heart disease.
Mazhari R; Hare JM
Prog Cardiovasc Dis; 2007; 49(6):387-95. PubMed ID: 17498519
[TBL] [Abstract][Full Text] [Related]
4. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease.
Yañez R; Lamana ML; García-Castro J; Colmenero I; Ramírez M; Bueren JA
Stem Cells; 2006 Nov; 24(11):2582-91. PubMed ID: 16873762
[TBL] [Abstract][Full Text] [Related]
5. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis.
Augello A; Tasso R; Negrini SM; Cancedda R; Pennesi G
Arthritis Rheum; 2007 Apr; 56(4):1175-86. PubMed ID: 17393437
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal stem cells and their potential as cardiac therapeutics.
Pittenger MF; Martin BJ
Circ Res; 2004 Jul; 95(1):9-20. PubMed ID: 15242981
[TBL] [Abstract][Full Text] [Related]
7. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation.
Le Blanc K; Ringdén O
Biol Blood Marrow Transplant; 2005 May; 11(5):321-34. PubMed ID: 15846285
[TBL] [Abstract][Full Text] [Related]
8. Immunological properties of mesenchymal stem cells and clinical implications.
Patel SA; Sherman L; Munoz J; Rameshwar P
Arch Immunol Ther Exp (Warsz); 2008; 56(1):1-8. PubMed ID: 18250975
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro.
Bocelli-Tyndall C; Bracci L; Spagnoli G; Braccini A; Bouchenaki M; Ceredig R; Pistoia V; Martin I; Tyndall A
Rheumatology (Oxford); 2007 Mar; 46(3):403-8. PubMed ID: 16920750
[TBL] [Abstract][Full Text] [Related]
10. Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues.
Yoo KH; Jang IK; Lee MW; Kim HE; Yang MS; Eom Y; Lee JE; Kim YJ; Yang SK; Jung HL; Sung KW; Kim CW; Koo HH
Cell Immunol; 2009; 259(2):150-6. PubMed ID: 19608159
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppressive properties of cloned bone marrow mesenchymal stem cells.
Xu G; Zhang L; Ren G; Yuan Z; Zhang Y; Zhao RC; Shi Y
Cell Res; 2007 Mar; 17(3):240-8. PubMed ID: 17325691
[TBL] [Abstract][Full Text] [Related]
12. 5-Azacytidine-treated human mesenchymal stem/progenitor cells derived from umbilical cord, cord blood and bone marrow do not generate cardiomyocytes in vitro at high frequencies.
Martin-Rendon E; Sweeney D; Lu F; Girdlestone J; Navarrete C; Watt SM
Vox Sang; 2008 Aug; 95(2):137-48. PubMed ID: 18557828
[TBL] [Abstract][Full Text] [Related]
13. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo.
Poncelet AJ; Vercruysse J; Saliez A; Gianello P
Transplantation; 2007 Mar; 83(6):783-90. PubMed ID: 17414713
[TBL] [Abstract][Full Text] [Related]
14. A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1.
Sheng H; Wang Y; Jin Y; Zhang Q; Zhang Y; Wang L; Shen B; Yin S; Liu W; Cui L; Li N
Cell Res; 2008 Aug; 18(8):846-57. PubMed ID: 18607390
[TBL] [Abstract][Full Text] [Related]
15. Emerging role for bone marrow derived mesenchymal stem cells in myocardial regenerative therapy.
Zimmet JM; Hare JM
Basic Res Cardiol; 2005 Nov; 100(6):471-81. PubMed ID: 16237508
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms involved in the therapeutic properties of mesenchymal stem cells.
Meirelles Lda S; Fontes AM; Covas DT; Caplan AI
Cytokine Growth Factor Rev; 2009; 20(5-6):419-27. PubMed ID: 19926330
[TBL] [Abstract][Full Text] [Related]
17. Histocompatibility testing of cultivated human bone marrow stromal cells - a promising step towards pre-clinical screening for allogeneic stem cell therapy.
Koppula PR; Chelluri LK; Polisetti N; Vemuganti GK
Cell Immunol; 2009; 259(1):61-5. PubMed ID: 19577229
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive properties of mesenchymal stem cells derived from bone marrow of patients with chronic myeloid leukemia.
Zhao ZG; Li WM; Chen ZC; You Y; Zou P
Immunol Invest; 2008; 37(7):726-39. PubMed ID: 18821219
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal stromal cells lose their immunosuppressive potential after allotransplantation.
Prigozhina TB; Khitrin S; Elkin G; Eizik O; Morecki S; Slavin S
Exp Hematol; 2008 Oct; 36(10):1370-6. PubMed ID: 18619727
[TBL] [Abstract][Full Text] [Related]
20. Increased proliferation of human synovial mesenchymal stem cells with autologous human serum: comparisons with bone marrow mesenchymal stem cells and with fetal bovine serum.
Nimura A; Muneta T; Koga H; Mochizuki T; Suzuki K; Makino H; Umezawa A; Sekiya I
Arthritis Rheum; 2008 Feb; 58(2):501-10. PubMed ID: 18240254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
